ATARA BIOTHERAPEUTICS, INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share amounts) Three Months Ended December 31, Twelve Months Ended ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform ...

Atara Biotherapeutics Announces Pricing of $16 Million Offering. THOUSAND OAKS, Calif., May 15, 2025--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its ...

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and ...

Atara Biotherapeutics (ATRA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

The share price of Atara Biotherapeutics Inc. began a slow climb up after the company experienced a steep drop earlier this month.. The Thousand Oaks drug maker saw its stock price decrease from a ...

Access Atara Biotherapeutics Inc stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.

Atara Biotherapeutics' headquarters in Thousand Oaks. The announcement by Atara Biotherapeutics Inc. that it was raising $36 million through a registered direct offering sat well with investors ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for ...

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and ...